Takeda

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

10 July 2023

Our new report contains a wealth of evidence for clinical value and cost-saving potential of next-generation sequencing (NGS) testing in lung cancer, and recommends that increased uptake requires focus on reimbursement, national standardisation, and new infrastructure

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

2 June 2023

In this report, we explore the status of access and uptake for NGS testing for lung cancer in Europe, develop the health economic case for NGS testing, and identify barriers and opportunities for widespread access.

Time to Tackle the Challenges around Combination Therapies for Cancer

29 March 2021

A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support use of…